Latest news with #CourtneyBreen
Yahoo
14 hours ago
- Business
- Yahoo
Bernstein Maintains Buy Rating on Gilead Sciences (GILD) Stock
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of Bernstein maintained a 'Buy' rating on the company's stock, retaining a price objective of $120.00. The analyst's rating is backed by a combination of factors associated with the promising prospects of the new drug, Yeztugo. The drug, which is also known as Lenacapavir, was recently approved by the FDA for use as a monotherapy in preventing HIV, which can significantly drive Gilead Sciences, Inc. (NASDAQ:GILD)'s growth, added the firm's analyst. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Furthermore, the innovation in Yeztugo's dosing paradigm is expected to enhance patient adherence as well as expand the PrEP market. Despite the concerns related to the drug's pricing, the analyst believes that the perceived financial burden might be mitigated by the insurance coverage. The analyst has also highlighted Gilead Sciences, Inc. (NASDAQ:GILD)'s strategic efforts to address logistical challenges. Overall, such factors, together with the drug's clinical differentiation and market receptivity, support the analyst's favourable outlook for the company's stock. Notably, the company has announced a strategic partnership agreement with the Global Fund to fight AIDS, Tuberculosis, and Malaria to supply lenacapavir, Gilead Sciences, Inc. (NASDAQ:GILD)'s twice-yearly injectable HIV-1 capsid inhibitor, for preventing HIV as pre-exposure prophylaxis (PrEP). Impax Asset Management, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Gilead Sciences, Inc. (NASDAQ:GILD) (Health Care) the company is owned due to its role in solving evolving heath care challenges through the development of new medical treatments for conditions as chronic diseases are on the rise. The company also has one of the highest systematic ESG scores in the portfolio. Gilead reported better-than-expected quarterly results, largely driven by strong revenue from its HIV franchise. The company also provided an optimistic earnings guidance for the next fiscal year, helping provide defensiveness amid a flurry of volatility.' While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
3 days ago
- Business
- Business Insider
Amgen (AMGN) Gets a Buy from Bernstein
In a report released on July 8, Courtney Breen from Bernstein maintained a Buy rating on Amgen, with a price target of $350.00. The company's shares closed yesterday at $295.27. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Moderna. According to TipRanks, Breen has an average return of 2.7% and a 50.00% success rate on recommended stocks. In addition to Bernstein, Amgen also received a Buy from BMO Capital's Evan Seigerman in a report issued on July 9. However, on July 10, Morgan Stanley maintained a Hold rating on Amgen (NASDAQ: AMGN).
Business Insider
4 days ago
- Business
- Business Insider
Bernstein Keeps Their Buy Rating on Eli Lilly & Co (LLY)
In a report released on July 8, Courtney Breen from Bernstein maintained a Buy rating on Eli Lilly & Co, with a price target of $1,100.00. The company's shares closed yesterday at $793.01. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Breen is a 2-star analyst with an average return of 2.7% and a 50.00% success rate. Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Moderna. In addition to Bernstein, Eli Lilly & Co also received a Buy from Guggenheim's Seamus Fernandez in a report issued yesterday. However, on June 23, Evercore ISI reiterated a Hold rating on Eli Lilly & Co (NYSE: LLY). Based on Eli Lilly & Co's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $12.73 billion and a net profit of $2.76 billion. In comparison, last year the company earned a revenue of $8.77 billion and had a net profit of $2.24 billion
Business Insider
7 days ago
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie (ABBV – Research Report) and Esperion (ESPR – Research Report). Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. AbbVie (ABBV) In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on AbbVie. The company's shares closed last Tuesday at $189.77. According to Breen is a 2-star analyst with an average return of 3.3% and a 61.9% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Gilead Sciences, and Merck & Company. AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $213.00, a 14.0% upside from current levels. In a report issued on July 1, Citi also maintained a Hold rating on the stock with a $205.00 price target. Esperion (ESPR) In a report released yesterday, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion, with a price target of $16.00. The company's shares closed last Tuesday at $1.17. According to Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.9% and a 29.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Adlai Nortye Ltd. Sponsored ADR, and Bioline RX Ltd Sponsored ADR. Esperion has an analyst consensus of Moderate Buy, with a price target consensus of $6.37.
Business Insider
7 days ago
- Business
- Business Insider
Bernstein Remains a Hold on Moderna (MRNA)
In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna. The company's shares closed yesterday at $32.54. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Moderna. According to TipRanks, Breen has an average return of 3.3% and a 61.90% success rate on recommended stocks. Currently, the analyst consensus on Moderna is a Hold with an average price target of $48.33, a 48.52% upside from current levels. In a report released on July 5, William Blair also maintained a Hold rating on the stock with a $0.00 price target.
